Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Sonoma Pharmaceuticals ( (SNOA) ) has provided an update.
On April 8, 2026, Sonoma Pharmaceuticals entered into a Manufacturing and Supply Agreement with Kenvue Brands LLC for the sale of its Microcyn® technology-based products in the United States. The contract becomes effective on October 24, 2025 and runs through March 2027, with the possibility of up to two additional one-year extensions upon mutual agreement.
The agreement provides Sonoma Pharmaceuticals with a defined multi-year framework for distributing its Microcyn® products through Kenvue’s U.S. network, potentially strengthening its commercial footprint and operational visibility in this market. The specified term and renewal options may offer greater planning certainty for both companies and could enhance Sonoma’s positioning in the competitive healthcare products sector.
The most recent analyst rating on (SNOA) stock is a Sell with a $2.00 price target. To see the full list of analyst forecasts on Sonoma Pharmaceuticals stock, see the SNOA Stock Forecast page.
Spark’s Take on SNOA Stock
According to Spark, TipRanks’ AI Analyst, SNOA is a Neutral.
The score is held down primarily by weak financial quality—ongoing losses, poor ROE, and continued negative operating/free cash flow—despite modest revenue growth and low leverage. Technicals add pressure due to a clear downtrend (below major moving averages with negative MACD), even though the stock is oversold. Corporate updates are constructive around portfolio and distribution momentum, but do not yet offset the current profitability and cash-burn profile; valuation is also constrained by losses (negative P/E) and no dividend support.
To see Spark’s full report on SNOA stock, click here.
More about Sonoma Pharmaceuticals
Sonoma Pharmaceuticals operates in the healthcare and pharmaceutical industry, focusing on Microcyn® technology-based products used in medical and consumer health applications. The company’s market presence is centered on supplying these specialty formulations to partners in the United States and potentially other regions through manufacturing and supply arrangements.
Average Trading Volume: 22,131
Technical Sentiment Signal: Sell
Current Market Cap: $3.96M
See more data about SNOA stock on TipRanks’ Stock Analysis page.